Company intelligence / Profile preview

NanoGhost

Ownership: Private
Development stage: Other

Overview

NanoGhost has demonstrated in preclinical models that its nanovesicle platform can selectively deliver therapeutics to solid tumors—including brain and pancreatic cancers—crossing the blood-brain barrier, reducing tumor size, and prolonging survival after a single treatment. The technology leverages the natural targeting ability of mesenchymal stem cell membranes to home in on cancerous tissue while carrying diverse therapeutic payloads.

Therapeutic areas: Oncology
Modalities: Nanovesicle-based therapySmall moleculeDNARNAPeptidesProteins
Industry: Biotech

Drug pipeline

3 assets

NG-2001

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Not publicly disclosed as of June 2025.

Beyond the preview

Go deeper on NanoGhost.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoGhost.

Explore the full profile